Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
Portfolio Pulse from Nabaparna Bhattacharya
RBC Capital Markets analyst Brian Abrahams has reiterated an Outperform rating on Regeneron Pharmaceuticals (NASDAQ: REGN) and raised the price target to $1,299 from $1,200. The analyst expects Dupixent's COPD sales to reach $20 billion by 2026, significantly higher than previous estimates. This is based on positive feedback from pulmonologists and a higher-than-expected number of eligible patients. The analyst also slightly raised the 2024 EPS estimate to $40.65.
June 13, 2024 | 1:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital Markets has raised the price target for Regeneron Pharmaceuticals to $1,299, driven by optimistic expectations for Dupixent's COPD sales, which are projected to reach $20 billion by 2026. The analyst also slightly increased the 2024 EPS estimate.
The raised price target and optimistic sales projections for Dupixent in the COPD market are likely to positively impact Regeneron's stock price in the short term. The slight increase in the 2024 EPS estimate also adds to the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100